Bovine Lactoferrin for Preterm Infant Sepsis: What the LIFT and Cochrane Updates Show

← Back to articles

Late-onset sepsis remains a major cause of morbidity and mortality in very low birthweight preterm infants. Bovine lactoferrin — an iron-binding glycoprotein abundant in colostrum — emerged in the 2010s as a promising preventive supplement after early Italian trials suggested large reductions in sepsis rates. Two large, well-conducted trials (ELFIN and LIFT) and an updated Cochrane review have since landed, and they sharply temper the early optimism. The headline finding for parents and clinicians: lactoferrin did not improve the outcomes that matter most — survival and major morbidity — and any residual sepsis benefit is small and of low certainty.

Why lactoferrin became plausible

Bovine lactoferrin is structurally similar to the human protein and survives processing, which makes it usable as a supplement. Mechanistically it has direct antibacterial activity (in part by sequestering iron that pathogens need), antifungal and immunomodulatory effects, and possibly a prebiotic effect favouring infant intestinal Bifidobacterium. The pivotal early trial, Manzoni 2009 (JAMA), randomized 472 very low birthweight Italian infants and reported late-onset sepsis in 5.9% on bovine lactoferrin alone and 4.6% on lactoferrin plus Lactobacillus rhamnosus GG, versus 17.3% on placebo — a risk ratio of about 0.34 for lactoferrin alone. Several smaller trials reproduced the direction of effect, and a 2017 Cochrane review of six trials found that lactoferrin decreased late-onset sepsis (risk ratio 0.59) and necrotizing enterocolitis, but rated the evidence as low-quality. The mechanism, the apparent magnitude of effect, and a clean safety profile made lactoferrin a leading candidate for NICU adoption.

The large trials told a different story

The ELFIN trial in the UK (2019, Lancet) randomized 2,203 very preterm infants to bovine lactoferrin or sucrose placebo daily until 34 weeks' postmenstrual age. Late-onset infection — the primary outcome — occurred in 29% of the lactoferrin group versus 31% of controls, a non-significant difference (adjusted risk ratio 0.95). Mortality and necrotizing enterocolitis showed no benefit.

The LIFT trial in Australia and New Zealand (2020, Lancet Child & Adolescent Health) randomized 1,542 very low birthweight infants to 200 mg/kg/day bovine lactoferrin or no supplement. Its primary outcome — survival to discharge free of major morbidity (brain injury, necrotizing enterocolitis, late-onset sepsis, or treated retinopathy) — occurred in 21% of the lactoferrin group versus 22% of controls (risk ratio 0.95, not significant). Notably, LIFT's own prespecified meta-analysis of 13 trials (5,609 infants) did find a statistically significant reduction in late-onset sepsis (risk ratio 0.79) even though the trial itself was null for its composite outcome — a hint that a real but modest sepsis effect may coexist with no effect on harder endpoints.

The updated 2020 Cochrane review (Pammi and Suresh) pooled 12 trials and 5,425 infants. It concluded that lactoferrin decreases late-onset sepsis (risk ratio 0.82, number-needed-to-treat about 25) but has no effect on necrotizing enterocolitis (risk ratio 1.10) or all-cause mortality (risk ratio 0.90), and it rated the sepsis finding as low-certainty — explicitly warning that publication bias and small, poor-quality studies may inflate the apparent benefit. In short: a small sepsis signal survives the pooling, but it does not translate into fewer deaths or less NEC, and confidence is low.

Why the early trials looked so positive

Two explanations dominate. First, small early trials with high control-arm event rates produce unstable effect estimates that tend to overstate benefit — a well-recognized pattern in neonatal and supplement trials, and exactly what the Cochrane authors flagged as likely publication bias. Second, baseline sepsis rates in many NICUs have fallen over the past 15 years thanks to better central-line care, antimicrobial stewardship, and breast-milk feeding; an intervention that helped at higher event rates may simply have less room to work now. Product heterogeneity (different lactoferrin sources, doses, and biological activity across trials) likely adds noise, but it does not explain the trial-size-dependent pattern.

Does any subgroup still benefit?

Possibly, but the evidence is weak. A 2020 pooled analysis of two Peruvian trials suggested lactoferrin protected the smallest infants (under 1000 g) and those receiving little human milk. A 2025 three-arm randomized trial in Pakistan (305 low-birthweight neonates) found no overall reduction in late-onset sepsis, though a lower-dose arm showed a nominal benefit that did not hold at the higher dose. And a 2024 network meta-analysis of agents to prevent necrotizing enterocolitis ranked lactoferrin as the most effective single agent specifically for NEC-associated sepsis — interesting, but hypothesis-generating. None of this rises to the level that would justify routine use.

What this means for practice

Current evidence does not support routine bovine lactoferrin supplementation in preterm infants for sepsis prevention. The large trials were null for their primary outcomes, and the pooled sepsis benefit is small, low-certainty, and unaccompanied by any mortality or NEC reduction. Some units may still consider it for specific high-risk infants given its low cost and clean safety record, but that is a judgement call, not an evidence-based standard.

The clearer wins in preventing late-onset sepsis in this population remain unglamorous: feeding parental own breast milk (donor milk where unavailable), strict central-line care bundles, and antimicrobial stewardship. Probiotic prophylaxis has stronger evidence for reducing NEC in preterm infants but remains contentious in the United States after the FDA's 2023 warning, issued following an infant death linked to a probiotic product given to a preterm neonate — a reminder that "natural" supplements are not automatically safe in this fragile population, and that any product used in the NICU should be a clinician's decision.

Sources

1. Manzoni P, Rinaldi M, Cattani S, et al. "Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial." JAMA, 2009;302(13):1421-1428. PMID 19809023.
2. ELFIN Trial Investigators Group. "Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial." Lancet, 2019;393(10170):423-433. PMID 30635141.
3. Tarnow-Mordi WO, Abdel-Latif ME, Martin A, et al. "The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial." Lancet Child & Adolescent Health, 2020;4(6):444-454. PMID 32407710.
4. Pammi M, Suresh G. "Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants." Cochrane Database of Systematic Reviews, 2020;3(3):CD007137. PMID 32232984.
5. Pammi M, Suresh G. "Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants." Cochrane Database of Systematic Reviews, 2017;6(6):CD007137. PMID 28658720.
6. Ochoa TJ, Loli S, Mendoza K, et al. "Effect of bovine lactoferrin on prevention of late-onset sepsis in infants <1500 g: a pooled analysis of individual patient data from two randomized controlled trials." Biochemistry and Cell Biology, 2021;99(1):14-19. PMID 32931708.
7. Ariff S, Soofi SB, Jiwani U, et al. "Evaluation of Bovine Lactoferrin for Prevention of Late-Onset Sepsis in Low-Birth-Weight Infants: A Double-Blind Randomized Controlled Trial." Nutrients, 2025;17(11):1774. PMID 40507041.
8. Chen J, Chen X, Huang X, et al. "Comparative efficacy of different single drugs to prevent necrotizing enterocolitis in preterm infants: an update systematic review and network meta-analysis." Frontiers in Nutrition, 2024;11:1452338. PMID 39315009.